Clinical Trial Update: Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas [Phase 1]

View source ↗

Summary

This Phase I trial conducted by AstraZeneca evaluates how food affects the pharmacokinetics and gastrointestinal tolerability of selumetinib in adolescents with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Neurofibromatosis Type 1 | Phase 1 | Status: ACTIVE_NOT_RECRUITING